Earlier this year, BioInsights hosted an expert roundtable featuring Dr Clive Glover (Pall), Dr Damian Marshall (Cell and Gene Therapy Catapult) and Cobra's CSO, Dr Daniel Smith to discuss providing innovation to viral vector bioprocessing if AAV vector supply is to meet increasing demand.
The key questions include:
- How to overcome the particular challenges in AAV downstream analytics development?
- How to improve the chromatography step in particular?
- How and where can these initiatives and methodologies be repurposed to benefit the lentiviral vector field?
Pictured: Daniel Smith, CSO, Cobra Biologics